Evidence map›Paper›PMID 32707170›Full record

ArticleInternational journal of antimicrobial agents2020

Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice.

Nicoleta Anghel, Pablo A Winzer, Dennis Imhof, Joachim Müller, Xavier Langa, Jessica Rieder, Lynn K Barrett, Rama Subba Rao Vidadala, Wenlin Huang, Ryan Choi and 8 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of antimicrobial agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor inInternational journal of molecular sciences · 2022
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Nicoleta AnghelInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 Bern, Switzerland.
Pablo A WinzerInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 Bern, Switzerland.
Dennis ImhofInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 Bern, Switzerland.
Joachim MüllerInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 Bern, Switzerland.
Xavier LangaDepartment of Developmental Biology and Regeneration, Institute of Anatomy, University of Bern, Baltzerstrasse 2, CH-3000 Bern, Switzerland.
Jessica RiederCentre for Fish and Wildlife Health (FIWI), Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.
Lynn K BarrettCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Rama Subba Rao VidadalaDepartment of Chemistry, University of Washington, Seattle, WA 98195, USA.
Wenlin HuangDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Ryan ChoiCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Mathew A HulversonCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Grant R WhitmanCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Samuel L ArnoldCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Wesley C Van VoorhisCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Kayode K OjoCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98109, USA.
Dustin J MalyDepartment of Chemistry, University of Washington, Seattle, WA 98195, USA.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Andrew HemphillInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 Bern, Switzerland. Electronic address: andrew.hemphill@vetsuisse.unibe.ch.
University of Washington · USUniversity of Bern · CH

Funding

Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4M
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0M
Coformulation of bumped kinase inhibitors with Artemisinin combination therapy will stop widespread transmission of artemisinin-resistant malaria strainsR21AI123690 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2017 to 2018
$490k
Development of Dual Efficacy Therapeutic Against Cryptosporidiosis and GiardiasisR21AI140881 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2019 to 2020
$477k
NIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NIAID NIH HHS R21 AI123690NIAID NIH HHS R21 AI140881
6 · The paper itself

Abstract

Bumped kinase inhibitors (BKIs) are effective against a variety of apicomplexan parasites. Fifteen BKIs with promising in vitro efficacy against Neospora caninum tachyzoites, low cytotoxicity in mammalian cells, and no toxic effects in non-pregnant BALB/c mice were assessed in pregnant mice. Drugs were emulsified in corn oil and were applied by gavage for 5 days. Five BKIs did not affect pregnancy, five BKIs exhibited ~15-35% neonatal mortality and five compounds caused strong effects (infertility, abortion, stillbirth and pup mortality). Additionally, the impact of these compounds on zebrafish (Danio rerio) embryo development was assessed by exposing freshly fertilised eggs to 0.2-50 μM of BKIs and microscopic monitoring of embryo development in a blinded manner for 4 days. We propose an algorithm that includes quantification of malformations and embryo deaths, and established a scoring system that allows the calculation of an impact score (S

Indexed as

AnimalsCalcium-Calmodulin-Dependent Protein KinasesCell LineCoccidiosisEmbryonic DevelopmentFemaleHep G2 CellsHumansMaleMiceMice, Inbred BALB CNaphthalenesNeosporaPiperidinesPregnancyPregnancy ComplicationsBKI 1369BKI-1553bumped kinase inhibitor 1294Calcium-Calmodulin-Dependent Protein KinasesNaphthalenesPiperidinesProtein KinasesPyrazolesPyrimidinesQuinolinesApicomplexan parasiteBumped kinase inhibitorCDPK1Embryo developmentPregnancyZebrafish

Identifiers

PMID32707170
PMCPMC8582287
OpenAlexW3044612303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.